2-(2-chloro-4-amino-phenyl)-1,2,3,4-tetrahydro-isoquinoline | 893750-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-(2-chloro-4-amino-phenyl)-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: 3-Chloro-4-[3,4-dihydro-2(1H)-isoquinolinyl]-aniline；3-chloro-4-(3,4-dihydro-1H-isoquinolin-2-yl)aniline
• CAS: 893750-76-0
• 化学式: C₁₅H₁₅ClN₂
• mdl: MFCD07365138
• 分子量: 258.75
• InChiKey: IPLFOSYVLVUIHX-UHFFFAOYSA-N

物化性质

• 沸点：
  462.3±45.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  3-甲基-2-糠酸 、 2-(2-chloro-4-amino-phenyl)-1,2,3,4-tetrahydro-isoquinoline 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成 N-[3-chloro-4-(3,4-dihydro-1H-isoquinolin-2-yl)phenyl]-3-methylfuran-2-carboxamide
  参考文献：
  名称：

  Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs

  摘要：

  This Letter describes the further lead optimization of the VU0486321 series of mGlu(1) positive allosteric modulators (PAMs), focused on addressing the recurrent issue of plasma instability of the phthalimide moiety. Here, we evaluated a number of phthalimide bioisosteres, and ultimately identified isoindolinones as the ideal replacement that effectively address plasma instability, while maintaining acceptable mGlu(1) PAM potency, DMPK profile, CNS penetration and mGluR selectivity. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.03.031
• 作为产物：
  描述：

  3-氯-4-氟硝基苯 在 palladium on activated charcoal 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 2-(2-chloro-4-amino-phenyl)-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs

  摘要：

  This Letter describes the further lead optimization of the VU0486321 series of mGlu(1) positive allosteric modulators (PAMs), focused on addressing the recurrent issue of plasma instability of the phthalimide moiety. Here, we evaluated a number of phthalimide bioisosteres, and ultimately identified isoindolinones as the ideal replacement that effectively address plasma instability, while maintaining acceptable mGlu(1) PAM potency, DMPK profile, CNS penetration and mGluR selectivity. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.03.031

文献信息

• QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS
  申请人：Bembenek Scott D.

  公开号：US20100204226A1

  公开（公告）日：2010-08-12

  Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

  公式（I）的喹唑啉酮化合物被描述为脯氨酸羟化酶抑制剂，这些化合物可用于制药组合物和治疗由脯氨酸羟化酶活性介导的疾病状态、紊乱和情况的方法。因此，这些化合物可用于治疗贫血、血管紊乱、代谢紊乱和伤口愈合等疾病。
• Quinazolinones as prolyl hydroxylase inhibitors
  申请人：Bembenek Scott D.

  公开号：US08937078B2

  公开（公告）日：2015-01-20

  Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

  描述了一种化合物，其化学式为（I）的喹唑啉酮化合物，可用作脯氨酸羟化酶抑制剂。这样的化合物可以用于制备药物组合物和治疗脯氨酸羟化酶活性介导的疾病状态、疾病和病情的方法。因此，这些化合物可以用于治疗贫血、血管疾病、代谢性疾病和伤口愈合等疾病。
• US8937078B2
  申请人：——

  公开号：US8937078B2

  公开（公告）日：2015-01-20
• [EN] QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS<br/>[FR] QUINAZOLINONES EN TANT QU'INHIBITEURS DE PROLYLE HYDROXYLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010093727A1

  公开（公告）日：2010-08-19

  Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
• [EN] CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES<br/>[FR] DÉRIVÉ D'AMINE CYCLIQUE ET SON UTILISATION À DES FINS MÉDICALES<br/>[JA] 環状アミン誘導体及びその医薬用途
  申请人：TORAY INDUSTRIES

  公开号：WO2019044940A1

  公开（公告）日：2019-03-07

  本発明は、レチノイド関連オーファン受容体γアンタゴニスト活性を有し、乾癬等の自己免疫疾患に対して治療効果又は予防効果を発揮する新規な化合物を提供することを目的としている。本発明は、下記に代表される環状アミン誘導体（Ｉ）、その立体異性体若しくはこれらの水和物、又は、それらの薬理学的に許容される塩を提供する。